P2B001 is an extended-release or ER formulation, meaning that the medication is formulated so that it is released slowly over time. It contains low doses of pramipexole (0.6 mg) and rasagiline (0.75 mg). Both compounds are approved therapies for Parkinson’s — marketed as Mirapex (pramipexole) and Azilect (rasagiline). The low doses used in P2B001 are not currently available on the market.
New Phase 3 Trial Data Back P2B001 as The... - Cure Parkinson's
New Phase 3 Trial Data Back P2B001 as Therapy for Early Parkinson’s
Written by
Farooqji
To view profiles and participate in discussions please or .
Read more about...
1 Reply
•
what is is considered early early Parkinson
Not what you're looking for?
You may also like...
First Patient Dosed in Phase 3 Trial of Buntanetap for Early Parkinson's
https://parkinsonsnewstoday.com/news/first-early-stage-parkinsons-patient-dosed-phase-3-trial-buntan
B 1 therapy for Parkinson’s
B 1 taken sublingually and followed that for 2 doses of 50mg, after receiving recommendations that...
Anyone participating in the Buntanetap Phase 3 trial?
com/cure-parkinsons/posts/148436640/annovis-bio-announces-first-patient-dosed-in-phase-3-trial-in-pa
Radical new therapy for Parkinson’s will use stem cell transplants
be available in five years.
https://www.theguardian.com/society/2022/dec/04/radical-new-therapy-for
Related Posts
Interview of Daphne Bryan following the publication of her book: “Parkinson’s and the B1 therapy”.
Dr. Tom Foltynie of Cure Parkinson’s Addresses Bydureon (Exanatide) Phase III Trial.
Anxious to hear any updates from Annovis Bio Butanetap phase 3 trial cohorts- parkinson’s and high-dose B 1 therapy
- Red light therapy trial results
